Information Provided By: 
Fly News Breaks for August 30, 2016
RIGL
Aug 30, 2016 | 14:03 EDT
As previously reported, Jefferies analyst Eun Yang raised her price target on Rigel Pharmaceuticals to $8.50 from $7.00, citing a higher probability for the success of fostamatinib after data from the first of two Phase 3 trials of the drug that she called a "much needed positive event" for the company. The firm keeps its Buy rating on Rigel shares, which are up 44.5% to $3.82 in afternoon trading.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
